Current mainstream treatment options for PD include L-3,4-dihydroxyphenylalanine monoamine oxidase-B (MAO-B) inhibitors, Catechol-O-methyl transferase (COMT) inhibitors, amantadine, and anticholinergic agents. This evidence concerns the gene COMT and Parkinson disease.